{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:49:49Z","timestamp":1786121389395,"version":"build-2736575974"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016658","name":"Plan Nacional sobre Drogas","doi-asserted-by":"publisher","award":["2020I062"],"award-info":[{"award-number":["2020I062"]}],"id":[{"id":"10.13039\/100016658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021-127833OB-I00"],"award-info":[{"award-number":["PID2021-127833OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.neuropharm.2026.111090","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:15:49Z","timestamp":1782918949000},"page":"111090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PM289, a synthetic CB2 in vitro receptor agonist, modulates morphine-induced antinociceptive effect and withdrawal syndrome in an animal model of osteoarthritic pain"],"prefix":"10.1016","volume":"299","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-0494","authenticated-orcid":false,"given":"M.M.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Paniagua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-8600","authenticated-orcid":false,"given":"P.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8789-9869","authenticated-orcid":false,"given":"C.","family":"Rodr\u00edguez-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"S\u00e1nchez-Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0739-7285","authenticated-orcid":false,"given":"D.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7210-6283","authenticated-orcid":false,"given":"E.","family":"Herrad\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-6934","authenticated-orcid":false,"given":"C.","family":"Goicoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2642-6969","authenticated-orcid":false,"given":"N.","family":"Jagerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-8378","authenticated-orcid":false,"given":"R.","family":"Gir\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111090_bib1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pnpbp.2012.10.013","article-title":"Different patterns of administration modulate propensity of methadone and buprenorphine to promote locomotor sensitization in mice","volume":"40","author":"Allouche","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2026.111090_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2014.10.016","article-title":"Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain","volume":"745","author":"Bag\u00fc\u00e9s","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"3A","key":"10.1016\/j.neuropharm.2026.111090_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9343(84)80101-1","article-title":"Combination analgesics","volume":"77","author":"Beaver","year":"1984","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111090_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1515\/nipt-2023-0016","article-title":"Activation of CB2R by synthetic CB2R agonist, PM289, improves brain endothelial barrier properties, decreases inflammatory response and enhances endothelial repair","volume":"2","author":"Bullock","year":"2023","journal-title":"NeuroImmune Pharm Ther"},{"key":"10.1016\/j.neuropharm.2026.111090_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080440","article-title":"Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint","volume":"8","author":"Burston","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2026.111090_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106560","article-title":"Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-retroviral toxic neuropathy","volume":"187","author":"Carey","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"10267","key":"10.1016\/j.neuropharm.2026.111090_bib7","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0140-6736(20)32340-0","article-title":"Global estimates of the need for rehabilitation based on the global burden of disease study 2019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Cieza","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.neuropharm.2026.111090_bib8","doi-asserted-by":"crossref","first-page":"9314","DOI":"10.3390\/ijms25179314","article-title":"Molecular sex differences and clinical gender efficacy in opioid use disorders: from pain management to addiction","volume":"25","author":"Concato","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111090_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/glia.20907","article-title":"Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1\/2, JNK, and NF-kappaB","volume":"58","author":"Correa","year":"2010","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111090_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/cmdc.201100568","article-title":"Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties","volume":"7","author":"Cumella","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neuropharm.2026.111090_bib11","first-page":"1","article-title":"Prescription opioid use among adults with chronic pain: united States, 2019","volume":"162","author":"Dahlhamer","year":"2021","journal-title":"Natl Health Stat Report"},{"key":"10.1016\/j.neuropharm.2026.111090_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.reth.2020.07.007","article-title":"Degenerative osteoarthritis a reversible chronic disease","volume":"15","author":"Di Nicola","year":"2020","journal-title":"Regen. Ther."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2026.111090_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejphar.2013.01.051","article-title":"Altered phosphorylation of GluA1 in the striatum is associated with locomotor sensitization induced by exposure to increasing doses of morphine","volume":"702","author":"Ding","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111090_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/can.2015.0001","article-title":"Expression of cannabinoid receptors in human osteoarthritic cartilage: implications for future therapies","volume":"1","author":"Dunn","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.neuropharm.2026.111090_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-2-29","article-title":"Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation","volume":"2","author":"Ehrhart","year":"2005","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2026.111090_bib16","series-title":"Directive 2010\/63\/EU on the Protection of Animals Used for Scientific Purposes: Severity Assessment Framework","year":"2019"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2026.111090_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pain.2004.08.004","article-title":"Pain related behaviour in two models of osteoarthritis in the rat knee","volume":"112","author":"Fernihough","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2026.111090_bib18","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.2147\/JPR.S317877","article-title":"TLR4 Antagonism reduces movement-induced nociception and ATF-3 expression in experimental osteoarthritis","volume":"14","author":"Ferreira-Gomes","year":"2021","journal-title":"J. Pain Res."},{"key":"10.1016\/j.neuropharm.2026.111090_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2019.04.011","article-title":"Comparison of the antinociceptive profiles of morphine and oxycodone in two models of inflammatory and osteoarthritic pain in rat","volume":"854","author":"Garcia","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.111090_bib20","doi-asserted-by":"crossref","first-page":"E508","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: a systematic analysis for the global burden of disease study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.neuropharm.2026.111090_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109075","article-title":"The challenges of treating osteoarthritis pain and opportunities for novel peripherally directed therapeutic strategies","volume":"213","author":"Gon\u00e7alves","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111090_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuropharm.2016.12.008","article-title":"Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists","volume":"116","author":"Grenald","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111090_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110257","article-title":"The cannabinoid CB2 agonist LY2828360 suppresses neuropathic pain behavior and attenuates morphine tolerance and conditioned place preference in rats","volume":"265","author":"Guenther","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111090_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109601","article-title":"Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain","volume":"237","author":"Guenther","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111090_bib23","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1111\/bph.70116","article-title":"Cannabinoid CB2 receptor-mediated analgesia: mechanism-based insights and therapeutic potential","volume":"182","author":"Guenther","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111090_bib26","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1016\/j.bmcl.2014.11.006","article-title":"The SAR development of substituted purine derivatives as selective CB2 agonists for the treatment of chronic pain","volume":"24","author":"Guidetti","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111090_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.9758\/cpn.2020.18.3.341","article-title":"A review of behavioral tests to evaluate different types of anxiety and anti-anxiety effects","volume":"18","author":"Himanshu","year":"2020","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2026.111090_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002922","article-title":"Prescription opioid use and misuse among adolescents and young adults in the United States: a national survey study","volume":"16","author":"Hudgins","year":"2019","journal-title":"PLoS Med."},{"issue":"18","key":"10.1016\/j.neuropharm.2026.111090_bib29","doi-asserted-by":"crossref","first-page":"10529","DOI":"10.1073\/pnas.1834309100","article-title":"Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS","volume":"100","author":"Ibrahim","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111090_bib30","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1073\/pnas.0409888102","article-title":"CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids","volume":"102","author":"Ibrahim","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.neuropharm.2026.111090_bib31","article-title":"Opioids for osteoarthritis pain: benefits and risks","volume":"58","author":"Ivers","year":"2012","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.neuropharm.2026.111090_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fnbeh.2020.00074","article-title":"Sex Differences and the role of estradiol in mesolimbic reward circuits and vulnerability to cocaine and opiate addiction","volume":"14","author":"Kokane","year":"2020","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111090_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuroscience.2021.11.007","article-title":"Cannabinoid receptor type 2 agonist reduces morphine tolerance via mitogen activated protein kinase phosphatase induction and mitogen activated protein kinase dephosphorylation","volume":"480","author":"Kong","year":"2022","journal-title":"Neurosci"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111090_bib34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.pain.2012.10.009","article-title":"Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate","volume":"154","author":"La Porta","year":"2013","journal-title":"Pain"},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111090_bib35","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/j.pain.0000000000000260","article-title":"Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain","volume":"156","author":"La Porta","year":"2015","journal-title":"Pain"},{"issue":"11","key":"10.1016\/j.neuropharm.2026.111090_bib36","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41386-020-0643-x","article-title":"Interruption of continuous opioid exposure exacerbates drug-evoked adaptations in the mesolimbic dopamine system","volume":"45","author":"Lefevre","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111090_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/mol.118.113233","article-title":"Cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal","volume":"95","author":"Li","year":"2019","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111090_bib38","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41467-023-37112-9","article-title":"Structural basis of selective cannabinoid CB2 receptor activation","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111090_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.117.109355","article-title":"Slowly signaling G protein-biased CB2 cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence","volume":"93","author":"Lin","year":"2018","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111090_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/ner.12473","article-title":"Spinal cord stimulation alters protein levels in the cerebrospinal fluid of neuropathic pain patients: a proteomic mass spectrometric analysis","volume":"19","author":"Lind","year":"2016","journal-title":"Neuromodulation"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111090_bib41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s40001-024-02207-6","article-title":"Involvement of CXCL12\/CXCR4 in CB2 receptor agonist-attenuated morphine tolerance in Walker 256 tumor-bearing rats with cancer pain","volume":"29","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.neuropharm.2026.111090_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108598","article-title":"Repeated morphine exposure activates synaptogenesis and other neuroplasticity-related gene networks in the dorsomedial prefrontal cortex of male and female rats","volume":"221","author":"Liu","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"17\u201318","key":"10.1016\/j.neuropharm.2026.111090_bib43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.lfs.2010.02.014","article-title":"A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss","volume":"86","author":"Lozano-Ondoua","year":"2010","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111090_bib44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/can.2022.0107","article-title":"The impact of JWH-133 on articular cartilage regeneration in osteoarthritis via metalloproteinase 13-dependent mechanism","volume":"8","author":"Malek","year":"2023","journal-title":"Cannabis Cannabinoid Res."},{"issue":"13","key":"10.1016\/j.neuropharm.2026.111090_bib45","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/s41386-023-01637-w","article-title":"Ventral tegmental area glutamate neurons establish a mu-opioid receptor gated circuit to mesolimbic dopamine neurons and regulate opioid-seeking behavior","volume":"48","author":"McGovern","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111090_bib46","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/j.1476-5381.2012.01948.x","article-title":"Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells","volume":"166","author":"Merighi","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111090_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13041-021-00801-x","article-title":"Cannabinoid receptors distribution in mouse cortical plasma membrane compartments","volume":"14","author":"Miranzadeh","year":"2021","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2026.111090_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108908","article-title":"Antinociceptive and chondroprotective effects of prolonged \u03b2-caryophyllene treatment in the animal model of osteoarthritis: focus on tolerance development","volume":"204","author":"Mlost","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111090_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111283","article-title":"CB2 agonism controls pain and subchondral bone degeneration induced by mono-iodoacetate: implications GPCR functional bias and tolerance development","volume":"136","author":"Mlost","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"3\u20134","key":"10.1016\/j.neuropharm.2026.111090_bib50","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1369-1600.2007.00071.x","article-title":"Place conditioning in a two- or three-conditioning compartment apparatus: a comparative study with morphine and U-50,488","volume":"12","author":"Morales","year":"2007","journal-title":"Addict. Biol."},{"issue":"14","key":"10.1016\/j.neuropharm.2026.111090_bib51","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1021\/acs.jmedchem.6b00397","article-title":"Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis","volume":"59","author":"Morales","year":"2016","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111090_bib52","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1476-5381.2011.01335.x","article-title":"Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human","volume":"164","author":"Morgan","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2026.111090_bib53","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/npp.2013.157","article-title":"Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine","volume":"38","author":"Navarrete","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111090_bib54","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41386-022-01322-4","article-title":"Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies","volume":"47","author":"Nielsen","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111090_bib55","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1073\/pnas.0504187103","article-title":"Peripheral cannabinoid receptor, CB2, regulates bone mass","volume":"103","author":"Ofek","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111090_bib56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/adb.12076","article-title":"Role of cannabinoid CB2 receptor in the reinforcing actions of ethanol","volume":"20","author":"Ortega-\u00c1lvaro","year":"2015","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2026.111090_bib57","article-title":"Modulation of morphine antinociceptive and rewarding effect by mirtazapine in an animal model of osteoarthritic pain","volume":"987","author":"Paniagua","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111090_bib58","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/0885-3924(94)90201-1","article-title":"The neuroleptics as adjuvant analgesics","volume":"9","author":"Patt","year":"1994","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.neuropharm.2026.111090_bib59","first-page":"S56","article-title":"A proof-of-concept (POC) study including experimental pain models (EPMS) to assess the effects of a CB2 agonist (LY2828360) in the treatment of patients with osteoarthritic (OA) knee pain","volume":"93","author":"Pereira","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"S1","key":"10.1016\/j.neuropharm.2026.111090_bib60","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","article-title":"Cannabinoid pharmacology: the first 66 years","volume":"147","author":"Pertwee","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111090_bib61","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","article-title":"Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside","volume":"6","author":"Rahn","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2026.111090_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803331","article-title":"Modulation of morphine analgesia, antinociceptive tolerance, and mu-opioid receptor binding by the cannabinoid CB2 receptor agonist O-1966","volume":"13","author":"Reichenbach","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111090_bib63","doi-asserted-by":"crossref","DOI":"10.1186\/ar2401","article-title":"Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis","volume":"10","author":"Richardson","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.neuropharm.2026.111090_bib64","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuroscience.2020.08.010","article-title":"Sciatic nerve ligation downregulates mitochondrial clusterin in the rat prefrontal cortex","volume":"446","author":"Rodr\u00edguez-Rivera","year":"2020","journal-title":"Neurosci"},{"issue":"9","key":"10.1016\/j.neuropharm.2026.111090_bib66","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1080\/1028415X.2021.1903672","article-title":"Perinatal undernourishment provokes long-lasting alterations of clusterin and fumarate hydratase expression in the rat nucleus accumbens","volume":"25","author":"Rodr\u00edguez-Rivera","year":"2022","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111090_bib65","doi-asserted-by":"crossref","DOI":"10.29219\/fnr.v65.5709","article-title":"Clusterin levels in undernourished SH-SY5Y cells","volume":"65","author":"Rodr\u00edguez-Rivera","year":"2021","journal-title":"Food Nutr. Res."},{"issue":"16","key":"10.1016\/j.neuropharm.2026.111090_bib67","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.3390\/jcm10163533","article-title":"Combination therapy for neuropathic pain: a review of recent evidence","volume":"10","author":"Serrano Afonso","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111090_bib68","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0030-1267855","article-title":"Pharmacology of nonsteroidal antiinflammatory drugs and opioids","volume":"27","author":"Slater","year":"2010","journal-title":"Semin. Interv. Radiol."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111090_bib69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.36076\/ppj.2008\/11\/201","article-title":"Combination opioid analgesics","volume":"11","author":"Smith","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.neuropharm.2026.111090_bib70","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/bs.apha.2017.05.003","article-title":"Cannabinoids and pain: sites and mechanisms of action","volume":"80","author":"Starowicz","year":"2017","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111090_bib71","doi-asserted-by":"crossref","unstructured":"Toddes C, Lefevre EM, Retzlaff CL, Zugschwert L, Khan S, Myhre E, Gauthier EA, Fernandez de Velasco EM, Kieffer BL, Rothwell PE. Mu opioid receptor expression by nucleus accumbens inhibitory interneurons promotes affiliative social behavior. bioRxiv [Preprint] 2024:2024.10.2024.28.620729. doi: 10.1101\/2024.10.28.620729.","DOI":"10.1101\/2024.10.28.620729"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111090_bib73","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.pbb.2005.01.021","article-title":"Molecular and cellular basis of cannabinoid and opioid interactions","volume":"81","author":"Vigan\u00f2","year":"2005","journal-title":"Pharmacol., Biochem. Behav."},{"issue":"11","key":"10.1016\/j.neuropharm.2026.111090_bib74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tips.2009.08.002","article-title":"The \"toll\" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia","volume":"30","author":"Watkins","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.111090_bib75","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","article-title":"Brain cannabinoid CB2 receptors modulate cocaine's actions in mice","volume":"14","author":"Xi","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111090_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/1744806917728227","article-title":"Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain","volume":"13","author":"Yuill","year":"2017","journal-title":"Mol. Pain"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111090_bib77","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/npp.2014.297","article-title":"Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and rats","volume":"40","author":"Zhang","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111090_bib78","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.3892\/mmr.2017.7479","article-title":"Effects of coadministration of low dose cannabinoid type 2 receptor agonist and morphine on vanilloid receptor 1 expression in a rat model of cancer pain","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol. Med. Rep."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826002649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826002649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:27:26Z","timestamp":1786076846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826002649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":77,"alternative-id":["S0028390826002649"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111090","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PM289, a synthetic CB2 in vitro receptor agonist, modulates morphine-induced antinociceptive effect and withdrawal syndrome in an animal model of osteoarthritic pain","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111090"}}